Announcements
- Cassava Sciences Issues Statement on Former Science Advisor
- Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
- Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
- Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
- Redemption Date Announced for Warrants
- Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
- Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
- Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
- No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
- Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.02 |
---|---|
High | 10.02 |
Low | 10.02 |
Bid | 10.08 |
Offer | 10.33 |
Previous close | 10.78 |
Average volume | 5.40k |
---|---|
Shares outstanding | 47.98m |
Free float | 44.81m |
P/E (TTM) | -- |
Market cap | 516.70m USD |
EPS (TTM) | -1.17 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 07:08 BST.
More ▼